Form 4: Foghorn Therapeutics CFO Resigns, Effective 2025

Kristian Humer has resigned as Chief Financial Officer of Foghorn Therapeutics Inc., with the change effective November 14, 2025.

Summary

• Kristian Humer, the Chief Financial Officer of Foghorn Therapeutics Inc. (FHTX), has resigned from his position.
• The resignation is effective November 14, 2025.
• This Form 4 filing serves as a voluntary exit filing, indicating that Humer will no longer be subject to Section 16 reporting requirements for Foghorn Therapeutics after the effective date.

Sentiment

Score: 4

Explanation: The filing reports the resignation of a key executive, the Chief Financial Officer, which can introduce uncertainty, though no specific negative reasons or immediate impacts are detailed within the filing itself.

Negatives

• The Chief Financial Officer, Kristian Humer, has resigned from Foghorn Therapeutics Inc., effective November 14, 2025.

Risks

• The departure of a key executive like the Chief Financial Officer may introduce uncertainty regarding financial strategy and operations, potentially impacting investor confidence or future financial performance.

Management Changes

Stakeholder Impact

• Shareholders: May experience uncertainty due to the upcoming leadership change in a critical financial role.
• Employees: May experience changes in financial leadership and reporting structure following the CFO's departure.

Key Dates

Recommendation

The resignation of the Chief Financial Officer introduces an element of uncertainty regarding financial leadership. While not inherently negative, investors should hold to monitor the company's announcement of a successor and any potential strategic shifts or impacts on financial operations and future capital raising efforts.

Keywords

Foghorn Therapeutics, FHTX, Kristian Humer, CFO resignation, executive change, Form 4, SEC filing, corporate governance